[Ip-health] Medicines Patent Pool Welcomes UNITAID Initiative to Fund Newer HIV Medicines
kmara at medicinespatentpool.org
Thu Jun 13 03:42:53 PDT 2013
GENEVA, 13 JUNE 2013: The Medicines Patent Pool welcomes UNITAID¹s
announcement that it will provide up to USD $77 million to scale up access
to newer, better tolerated HIV medicines.
Simplified, ³fixed-dose combination² treatments based on tenofovir (TDF)
are recommended by the World Health Organization over older HIV medicines
that carry more unwanted side effects. UNITAID has committed funds to help
people living with HIV switch to these preferred treatment regimens.
The Medicines Patent Pool in July 2011 signed an agreement with Gilead
Sciences that helped to increase the availability of lower-cost TDF in
many developing countries. Generic manufacturers working with the Patent
Pool are already supplying more affordable versions of TDF in 20 more
countries than they could prior to the
July 2011 agreement.
Lower-cost generic tenofovir will help UNITAID and other funders and
treatment providers expand access to these critically important new
The Medicines Patent Pool is in further negotiations with several other
pharmaceutical companies to facilitate affordable production of other
important HIV medicines. The MPP¹s most recent agreement covered a
WHO-recommended treatment for children living with HIV.
Read more from UNITAID here:
More information about the Ip-health